Arabic Arabic English English French French German German
dark

Largest Phase III Hemophilia Gene Therapy Trial Yields Positive Results

​The results over the two-year evaluation period for its Phase III GENEr8-1 trial showed consistent clinical benefit from using valoctocogene roxaparvovec.  Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Sanofi, Exscientia Expand in AI with Up-to-$5.2B Cancer, Immunology Alliance

Next Post

Exact Sciences Acquires PreventionGenetics to Accelerate Availability of Hereditary Cancer Testing for More Patients

Related Posts
Total
0
Share